What FDA’s New Biosimilar Development Push Could Mean for Infusion Practices in 2026

IBS vs. IBD: What’s the Difference, and When Could Biologic Treatment Be Part of the Conversation?

Key Considerations When Launching or Expanding an In-Office Infusion Program

Spring Allergies and Asthma: When Is It Time to Talk to Your Doctor About Biologic Therapy?

2026: Is Your Practice Ready for In-Office Biologics? Operational Signs It’s Time to Expand

2026: Is Your Practice Ready for In-Office Biologics? Operational Signs It’s Time to Expand

What a Fully Managed Biologics Program Actually Takes Off Your Staff’s Plate

How to Talk With Your Care Team If Biologic Treatment Doesn’t Feel Like It’s Working Yet

Summer Travel and Biologic Therapy: What Patients Should Know Before You Go

Preparing Specialty Practices for a More Cost-Conscious Biologics Market